Skip to main content
John F. Valentine
( out of 57 reviews )

John F. Valentine, MD

Languages spoken: English

Clinical Locations

University of Utah Hospital

Gastroenterology Endoscopy Center
801-213-9797

University of Utah Hospital

Gastroenterology, Area E
801-213-9797
  • John F. Valentine, MD, is a Professor of Medicine at the University of Utah School of Medicine in the Division of Gastroenterology, Hepatology and Nutrition and specializes in ulcerative colitis and Crohn’s disease. His clinical interests and expertise are in inflammatory diseases of the intestinal tract that include inflammatory bowel disease (ulcerative colitis and Crohn’s disease) and celiac disease.

    Dr. Valentine received his M.D. degree from the University of Texas Medical School at Houston in 1985. He received his training in Internal Medicine at the Medical College of Virginia-Virginia Commonwealth University Medical Center and his training in Gastroenterology at the University of Florida. While on faculty at the University of Florida, he rose to the position of Professor of Medicine, served as the Chief of the Gastroenterology Section at the Malcom Randal Veterans Administration Medical Center, and founded the Southeastern Center for Inflammatory Bowel Disease. He remains active with the Crohn’s and Colitis Foundation of America and has served a Co-Chair of the CCFA patient education committee and was a member of the editorial board for the journal Inflammatory Bowel Disease. Dr. Valentine is a Fellow in the American Gastroenterological Association and the director of the University of Utah Inflammatory Bowel Disease Center. Dr. Valentine has extensive experience with treating patients with inflammatory bowel disease and he is developing laboratory research and clinical trials in ulcerative colitis and Crohn’s disease in order to expand the understanding and treatment options for patients with these diseases.

    Board Certification

    American Board of Internal Medicine

    Patient Rating

    5.0 /5
    ( out of 57 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 14, 2023
    UH HOSPITALS AND CLINICS

    Very positive.

    August 05, 2023
    UH HOSPITALS AND CLINICS

    Highly recommended

    August 04, 2023
    SUGAR HOUSE HEALTH CENTER

    Excellent doctor. Cares about patients.

    July 08, 2023
    UH HOSPITALS AND CLINICS

    An exceptional experience

    May 31, 2023
    UH HOSPITALS AND CLINICS

    Ive been dealing with Crohns for over 15 years at this point and he told me things Ive never heard from any other doctor. Eager to try out a new approach, but really havent moved forward with anything yet. Seems promising though!

    May 21, 2023
    UH HOSPITALS AND CLINICS

    Great Dr.he really Listen to all my questions give me answers.

    April 27, 2023
    SUGAR HOUSE HEALTH CENTER

    Great healthcare provider. Not only does Dr Valentine provide great medical care, he does so with a caring manner.

    April 17, 2023
    UH HOSPITALS AND CLINICS

    Dr is so kind and helpful.

    April 11, 2023
    SUGAR HOUSE HEALTH CENTER

    He is one of the best doctors I have ever had. He cares very much and he is very thorough.

  • John F. Valentine, MD, is a Professor of Medicine at the University of Utah School of Medicine in the Division of Gastroenterology, Hepatology and Nutrition and specializes in ulcerative colitis and Crohn’s disease. His clinical interests and expertise are in inflammatory diseases of the intestinal tract that include inflammatory bowel disease (ulcerative colitis and Crohn’s disease) and celiac disease.

    Dr. Valentine received his M.D. degree from the University of Texas Medical School at Houston in 1985. He received his training in Internal Medicine at the Medical College of Virginia-Virginia Commonwealth University Medical Center and his training in Gastroenterology at the University of Florida. While on faculty at the University of Florida, he rose to the position of Professor of Medicine, served as the Chief of the Gastroenterology Section at the Malcom Randal Veterans Administration Medical Center, and founded the Southeastern Center for Inflammatory Bowel Disease. He remains active with the Crohn’s and Colitis Foundation of America and has served a Co-Chair of the CCFA patient education committee and was a member of the editorial board for the journal Inflammatory Bowel Disease. Dr. Valentine is a Fellow in the American Gastroenterological Association and the director of the University of Utah Inflammatory Bowel Disease Center. Dr. Valentine has extensive experience with treating patients with inflammatory bowel disease and he is developing laboratory research and clinical trials in ulcerative colitis and Crohn’s disease in order to expand the understanding and treatment options for patients with these diseases.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Gastroenterology
    Board Certification
    American Board of Internal Medicine

    Education history

    Fellowship Gastroenterology - University of Florida College of Medicine Fellow
    Internal Medicine - Medical College of Virginia Intern/Resident
    Professional Medical Medicine - University of Texas Medical School at Houston M.D.
    Microbiology - University of Texas at Arlington B.S.

    Selected Publications

    Journal Article

    1. Levic DS, Niedzwiecki D, Kandakatla A, Karlovich NS, Juneja A, Park J, Stolarchuk C, Adams S, Willer JR, Schaner MR, Lian G, Beasley C, Marjoram L, Flynn AD, Valentine JF, Onken JE, Sheikh SZ, Davis EE, Evason KJ, Garman KS, Bagnat M (). TNF promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF response. medRxiv (Preprint)  2024 Feb 6:2024. (Epub ahead of print) medRxiv.
    2. Chulkina M, Rohmer C, McAninch S, Panganiban RP, Villger R, Portolese A, Ciocirlan J, Yang W, Cohen C, Koltun W, Valentine JF, Cong Y, Yochum G, Beswick EJ, Pinchuk IV (2024). Increased activity of MAPKAPK2 within mesenchymal cells as a target for inflammation associated fibrosis in Crohn's Disease. J Crohns Colitis. (Read full article)
    3. Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, Feagan BG, Neustifter B, Kadali H, Nazarey P, James A, Jairath V, Qasim Khan RM (2023). Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). Clin Gastroenterol Hepatol. (Read full article)
    4. Toy G, Colletier K, Hale G, Valentine J, Gawron AJ, Sossenheimer M, Peterson K, Aparicio R, Fang JC (2023). Incidence of retained biopsy specimens after esophagogastroduodenoscopy and colonoscopy. Endosc Int Open, 11(7), E653-E659. (Read full article)
    5. Mohan BP, Fatima N, Khan SR, Kassab L, Chandan S, Asokkumar R, Valentine JF, Navaneethan U, Kochhar GS, Ma C, Jairath V, Singh S (2023). Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.   PMID: 37207296 DOI: 10.14309/ajg.0000000000002328 . Am J Gastroenterol. (Read full article)
    6. Lebish EJ, Morgan NJ, Valentine JF, Beswick EJ (2022). MK2 Inhibitors as a Potential Crohn's Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity. Pharmaceuticals (Basel), 15(12). (Read full article)
    7. Tsai HY, Bronner MP, March JK, Valentine JF, Shroyer NF, Lai LA, Brentnall TA, Pan S, Chen R (2022). Metabolic targeting of NRF2 potentiates the efficacy of the TRAP1 inhibitor G-TPP through reduction of ROS detoxification in colorectal cancer. Cancer Lett, 549, 215915. (Read full article)
    8. Sandborn WJ, Pans J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baa C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S, BERGAMOT Study Group (2022). Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. (Read full article)
    9. Papamichael K, Jairath V, Zou G, Cohen B, Ritter T, Sands B, Siegel C, Valentine J, Smith M, Vande Casteele N, Dubinsky M, Cheifetz A (2022). Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open, 12(4), e057656. (Read full article)
    10. Tse CS, Van Citters AD, Ricci B, Freundlich NZ, Lee M, Shah SA, Melmed GY, Siegel CA, van Deen WK, IBD Qorus (2021). Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease. J Crohns Colitis, 16(3), 379-388. (Read full article)
    11. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group (2021). Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol, 7(2), 128-140. (Read full article)
    12. Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Pans J, HIBISCUS Study Group (2021). Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol, 7(1), 17-27. (Read full article)
    13. Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG, LAUREL Study Group (2021). Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol, 7(1), 28-37. (Read full article)
    14. Ost KS, OMeara TR, Stephens WZ, Chiaro T, Zhou H, Penman J, Bell R, Catanzaro JR, Song D, Singh S, Call DH, Hwang-Wong E, Hanson KE, Valentine JF, Christensen KA, OConnell RM, Cormack B, Ibrahim AS, Palm NW, Noble SM, Round JL (2021). Adaptive immunity induces mutualism between commensal eukaryotes. Nature, 596(7870), 114-118. (Read full article)
    15. Lewis JD, Sandler R, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF, Hanson J, Suskind D, Meyer A, Compher CW, Bewtra M, Saxena A, Dobes A, Cohen B, Flynn AD, Fischer M, Saha S, Swaminath A, Yacyshyn B, Scherl E, Horst S, Curtis JR, Braly K, Nessel L, McCauley M, McKeever L, Herfarth H, DINE-CD Study Group (2021). A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults with Crohn's Disease. Gastroenterology, 161, 837-852.e9. (Read full article)
    16. Somineni HK, Nagpal S, Venkateswaran S, Cutler DJ, Okou DT, Haritunians T, Simpson CL, Begum F, Datta LW, Quiros AJ, Seminerio J, Mengesha E, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Iskandar H, Dryden GW, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kuemmerle JF, Lazarev M, Li E, Mannon P, Moulton DE, Newberry RD, Patel AS, Pekow J, Saeed SA, Valentine JF, Wang MH, McCauley JL, Abreu MT, Jester T, Molle-Rios Z, Palle S, Scherl EJ, Kwon J, Rioux JD, Duerr RH, Silverberg MS, Zwick ME, Stevens C, Daly MJ, Cho JH, Gibson G, McGovern DPB, Brant SR, Kugathasan S (2021). Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease. Am J Hum Genet, 108(3), 431-445. (Read full article)
    17. Samadder NJ, Valentine JF, Guthery S, Singh H, Bernstein CN, Leighton JA, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Burt RW, Curtin K, Smith KR (2018). Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol, 17(9), 1807-1813.e1. (Read full article)
    18. Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF, Porter N, Martens E, OConnell R, Jacob V, Scherl E, Crawford C, Stephens WZ, Casjens SR, Longman RS, Round JL (2018). Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. Cell Host Microbe, 25(2), 285-299.e8. (Read full article)
    19. Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD, Clinical Research Alliance of the Crohns and Colitis Foundation (2018). Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology, 155(4), 1098-1108.e9. (Read full article)
    20. Johnson J, Affolter K, Boynton K, Chen X, Valentine J, Peterson K (2017). CMV Disease in IBD: Comparison of Diagnostic Tests and Correlation with Disease Outcome. Inflamm Bowel Dis, 24(7), 1539-1546. (Read full article)
    21. Brant SR, Okou DT, Simpson CL, Cutler DJ, Haritunians T, Bradfield JP, Chopra P, Prince J, Begum F, Kumar A, Huang C, Venkateswaran S, Datta LW, Wei Z, Thomas K, Herrinton LJ, Klapproth JA, Quiros AJ, Seminerio J, Liu Z, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Dryden GW, Hanson JS, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kwon JH, Lazarev M, Li E, Mack D, Mannon P, Moulton DE, Newberry RD, Osuntokun BO, Patel AS, Saeed SA, Targan SR, Valentine JF, Wang MH, Zonca M, Rioux JD, Duerr RH, Silverberg MS, Cho JH, Hakonarson H, Zwick ME, McGovern DP, Kugathasan S (2017). Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology, 152(1), 206-217.e2. (Read full article)
    22. Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S, Chopra P, Alexander JS, Baldassano RN, Cross RK, Dassopoulos T, Dhere TA, Duerr RH, Hanson JS, Hou JK, Hussain SZ, Isaacs KL, Kachelries KE, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kumar A, Kwon JH, Lazarev M, Mannon P, Moulton DE, Osuntokun BO, Patel A, Rioux JD, Rotter JI, Saeed S, Scherl EJ, Silverberg MS, Silverman A, Targan SR, Valentine JF, Wang MH, Simpson CL, Bridges SL, Kimberly RP, Rich SS, Cho JH, Rienzo AD, Kao LWH, McGovern DPB, Brant SR, Kugathasan S (2015). Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology, 149(6), 1575-1586. (Read full article)
    23. Runtsch MC, Hu R, Alexander M, Wallace J, Kagele D, Petersen C, Valentine JF, Welker NC, Bronner MP, Chen X, Smith DP, Ajami NJ, Petrosino JF, Round JL, OConnell RM (2015). MicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitis. Oncotarget, 6(30), 28556-72. (Read full article)
    24. Melmed GY, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S (2015). Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis, 21(8), 1809-16. (Read full article)
    25. Koboziev I, Jones-Hall Y, Valentine JF, Webb CR, Furr KL, Grisham MB (2015). Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases. Inflamm Bowel Dis, 21(7), 1652-73. (Read full article)
    26. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R (2015). Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis, 21(6), 1329-40. (Read full article)
    27. Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, Sobel E, Atkinson MA, Clare-Salzler MJ (2014). Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol, 193(3), 1024-34.
    28. Faubion WA Jr, Fletcher JG, OByrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME (2013). EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol, 108(12), 1891-900. (Read full article)
    29. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT (2013). Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 11(3), 286-92; quiz e24. (Read full article)
    30. Ukhanova M, Culpepper T, Baer D, Gordon D, Kanahori S, Valentine J, Neu J, Sun Y, Wang X, Mai V (2012). Gut microbiota correlates with energy gain from dietary fiber and appears to be associated with acute and chronic intestinal diseases. Clin Microbiol Infect, 18, 62-66.
    31. Wang MH, Okazaki T, Kugathasan S, Cho JH, Isaacs KL, Lewis JD, Smoot DT, Valentine JF, Kader HA, Ford JG, Harris ML, Oliva-Hemker M, Cuffari C, Torbenson MS, Duerr RH, Silverberg MS, Rioux JD, Taylor KD, Nguyen GC, Wu Y, Datta LW, Hooker S, Dassopoulos T, Kittles RA, Kao LW, Brant SR (2012). Contribution of higher risk genes and European admixture to Crohn's disease in African Americans. Inflamm Bowel Dis, 18(12), 2277-87. (Read full article)
    32. Davis MK, Valentine JF, Weinstein DA, Polyak S (2010). Antibodies to CBir1 are associated with glycogen storage disease type Ib. J Pediatr Gastroenterol Nutr, 51(1), 14-8. (Read full article)
    33. Ahmadi A, Li Q, Muller K, Collins D, Valentine JF, Drane W, Polyak S (2010). Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflamm Bowel Dis, 16(6), 974-81. (Read full article)
    34. Dassopoulos T, Nguyen GC, Talor MV, Datta LW, Isaacs KL, Lewis JD, Gold MS, Valentine JF, Smoot DT, Harris ML, Oliva-Hemker M, Bayless TM, Burek CL, Brant SR (2010). NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. Am J Gastroenterol, 105(2), 378-86. (Read full article)
    35. Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, Humphries TJ (2009). Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut, 58(10), 1354-62. (Read full article)
    36. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ (2005). Sargramostim for active Crohn's disease. N Engl J Med, 352(21), 2193-201. (Read full article)
    37. Naser SA, Ghobrial G, Romero C, Valentine JF (2004). Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet, 364(9439), 1039-44. (Read full article)
    38. Valentine JF (2001). Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo. Am J Physiol Gastrointest Liver Physiol, 281(4), G1044-50. (Read full article)

    Abstract

    1. Mach A, Glover S, Valentine JF (2012). GM-CSF and IL23 Protect the Intestinal Epithelial Barrier from Disruption by IFN Treatment. [Abstract]. DDW- Sandiego, CA.
    2. Gaidos JKJ, Sultan S, Dahl W, Valentine JF (Dec 9-12, 2010). Vitamin D Deficiency in Inflammatory Bowel Disease. Advances in IBD Annual CCFA Meeting. Ft. Lauderdale, FL. [Abstract].

    Patent

    1. Valentine JF (2004). Manganese superoxide dismutase regulatory elements and the uses thereof. U.S. Patent No. 6,800,458. Washington, D.C.:U.S. Patent and Trademark Office.